This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with ne
Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer c
Crystal structure of Glypican-2 core protein in complex with D3 Fab Descriptor: D3 Fab Heavy chain, D3 Fab Light Chain, Glypican-2, ... Authors: Raman, S, Maris, J.M, Bosse, K.R, Julien, J.P. Deposit
